کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
4001442 1259409 2006 4 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: History and rationale
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی تومور شناسی
پیش نمایش صفحه اول مقاله
Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: History and rationale
چکیده انگلیسی

Angiogenesis inhibition with bevacizumab and other agents of this class are showing significant activity in a variety of cancers. In prostate cancer, the single agent activity has been low, but the addition of these agents to chemotherapy may be the area in which they provide their greatest clinical benefit. An ongoing study conducted by the Cancer and Leukemia Group B will test this approach in men with metastatic hormone refractory prostate cancer. Future studies may test the efficacy of anti-angiogenic strategies in earlier stage disease as well as in combination with other approaches. This review will highlight the clinical experience to date with angiogenesis inhibitors in prostate cancer and the ongoing studies.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Urologic Oncology: Seminars and Original Investigations - Volume 24, Issue 3, May–June 2006, Pages 250–253
نویسندگان
, , ,